SCHEMBL6743780

SCHEMBL6743780

CCOC(=O)CCOc1c[c]ncn1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYSLTR2 Q9NS75 2/20 0.38
CYSLTR1 Q9Y271 2/20 0.38
LTA4H P09960 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
CYP4F2 P78329 2/20 0.36
CYP4A11 Q02928 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
TNF P01375 2/20 0.34
CYP1A2 P05177 1/20 0.34
GAA P10253 2/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
P2RY12 Q9H244 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6746899 0.86 KDM4E (0.48) SMN1; SMN2ALDH1A1KDM4EGAAPDE3B
SCHEMBL6746858 0.85 KMT2A (0.37) LTA4HSMN1; SMN2ALDH1A1PDE3BPDE3A
SCHEMBL6743776 0.73 L3MBTL1 (0.44) SMN1; SMN2ALDH1A1KDM4EL3MBTL1CYP1A2
SCHEMBL6745452 0.72 SMN1; SMN2 (0.40) SMN1; SMN2ALDH1A1KDM4ECYP1A2
SCHEMBL28034661 0.70 CYP1A2 (0.47) ALDH1A1KDM4ECYP1A2GAANPSR1
SCHEMBL24936702 0.66 TDP1 (0.51) CYSLTR2CYSLTR1LTA4HALDH1A1L3MBTL1
SCHEMBL4457893 0.66 LTA4H (0.48) CYSLTR2CYSLTR1LTA4HALDH1A1L3MBTL1
SCHEMBL3951838 0.65 L3MBTL1 (0.66) LTA4HKDM4EL3MBTL1RAB9A
SCHEMBL38664 0.65 LTA4H (0.60) LTA4HSMN1; SMN2ALDH1A1GAARAB9A
SCHEMBL7692040 0.64 LTA4H (0.52) CYSLTR2CYSLTR1LTA4HL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040023805-A1 Substituted phenyluracils ANDREE ROLAND (DE) 2004-02-05 US disclosed
US-6649760-B2 Herbicides BAYER AKTIENGESELLSCHAFT (DE) 2003-11-18 US disclosed
CN-1420873-A Substituted phenyluracils BAYER AG (DE) 2003-05-28 CN disclosed
EP-1272478-A1 SUBSTITUTED PHENYLURACILS Bayer Aktiengesellschaft (DE) 2003-01-08 EP disclosed
US-20020173425-A1 Substituted phenyluracils BAYER AKTIENGESELLSCHAFT (DE) 2002-11-21 US disclosed
WO-2001077084-A1 SUBSTITUTED PHENYLURACILS BAYER CROPSCIENCE AG (DE) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173425-A1 Substituted phenyluracils DPYD, POP1, G6PD CYSLTR2 3919/4885CYSLTR1 3628/4885LTA4H 4639/4885
US-20040023805-A1 Substituted phenyluracils DPYD, POP1, G6PD CYSLTR2 3919/4885CYSLTR1 3628/4885LTA4H 4639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.